An open study of the pharmacokinetics and the tolerability of raclopride extended release capsules in psychiatric patients

Joseph Patrick McEvoy, Gunilla Movin-Osswald, Gunilla Uppfeldt, Tracy Williams, Susan Dutcher, Joy Apperson

Research output: Contribution to journalArticle

2 Scopus citations


Following a 4-7 day drug-free washout period, eight male inpatients took an extended-release (ER) formulation of raclopride. After the initial 8 mg dose on day 1 of the study, repeated plasma samples were collected over the ensuing 36 h. Subsequently, patients received raclopride 8 mg b.i.d. through day 7, 12 mg b.i.d. through day 14, and, if tolerated, 16 mg b.i.d. through day 21. On days 7, 14, and 21, repeated plasma samples were drawn over the 12 h following the morning dose. Relative to the previously studied immediate release form of raclopride, the ER formulation delayed and extended the absorption of raclopride, and produced lower maximum raclopride concentrations. Linear kinetics were preserved across the dose range studied. Two patients could not tolerate the highest raclopride dose because of extrapyramidal side effects.

Original languageEnglish (US)
Pages (from-to)371-374
Number of pages4
Issue number2-3
StatePublished - Sep 1 1993
Externally publishedYes



  • Pharmacokinetics
  • Psychiatric patients
  • Raclopride
  • Tolerability

ASJC Scopus subject areas

  • Pharmacology

Cite this